HUTCHMED (China) Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
HCM Nasdaq 2830 www.hutch-med.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for HUTCHMED (China) Limited

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - May 21st, 2026 4:00 am
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - May 21st, 2026 4:00 am
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Apr 29th, 2026 6:35 am
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia - Apr 29th, 2026 4:00 am
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Apr 28th, 2026 9:12 pm
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - Apr 23rd, 2026 6:35 am
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - Apr 8th, 2026 6:00 pm
Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today? - Mar 31st, 2026 1:39 am
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - Mar 22nd, 2026 6:00 pm
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... - Mar 11th, 2026 7:02 pm
Sector Update: Health Care Stocks Decline Premarket Monday - Mar 9th, 2026 7:20 am
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - Mar 9th, 2026 3:30 am
Hutchmed price target lowered to $21 from $22 at BofA - Mar 7th, 2026 6:16 am
Intended Retirement of Independent Non-executive Director and changes of composition of board committees - Mar 6th, 2026 1:30 am
HUTCHMED H2 Earnings Call Highlights - Mar 5th, 2026 7:07 pm
HUTCHMED Reports 2025 Full Year Results and Business Updates - Mar 5th, 2026 4:00 am
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - Mar 4th, 2026 1:30 am
HUTCHMED to Announce 2025 Final Results - Feb 6th, 2026 1:30 am
Paycom Software, Inc. (PAYC): A Bull Case Theory - Feb 2nd, 2026 5:49 pm
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - Jan 13th, 2026 9:00 pm